Mark Plavsic's most recent trade in Aura Biosciences Inc was a trade of 112,661 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aura Biosciences Inc | Mark Plavsic | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 112,661 | 112,661 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Mark Plavsic | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 62,339 | 243,736 | - | 0 | Common Stock | |
| Aura Biosciences Inc | Mark Plavsic | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 5.05 per share. | 17 Feb 2026 | 15,890 | 181,397 | - | 5.1 | 80,245 | Common Stock |
| Aura Biosciences Inc | Mark Plavsic | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 6.35 per share. | 16 Oct 2025 | 12,169 | 197,287 | - | 6.3 | 77,273 | Common Stock |
| Aura Biosciences Inc | Mark Plavsic | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 7.75 per share. | 18 Feb 2025 | 2,151 | 209,456 | - | 7.7 | 16,670 | Common Stock |
| Aura Biosciences Inc | Mark Plavsic | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 90,475 | 211,607 | - | 0 | Common Stock | |
| Aura Biosciences Inc | Mark Plavsic | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 59,525 | 59,525 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Mark Plavsic | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 9.85 per share. | 16 Oct 2024 | 7,383 | 121,132 | - | 9.9 | 72,723 | Common Stock |
| Fate Therapeutics Inc | Mark Plavsic | Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 5.24 per share. | 10 Jan 2023 | 3,418 | 123,705 (0%) | 0% | 5.2 | 17,910 | Common Stock |
| Fate Therapeutics Inc | Mark Plavsic | Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 24.61 per share. | 05 Jul 2022 | 3,719 | 127,123 (0%) | 0% | 24.6 | 91,525 | Common Stock |
| Fate Therapeutics Inc | Mark Plavsic | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 53,058 | 53,058 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Mark Plavsic | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 33,302 | 130,842 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Mark Plavsic | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 59,540 | 97,540 (0%) | 0% | 0 | Common Stock |